HgbA1c levels were collected every 6 months ; the 4-year Kaplan-Meier estimate for incidence of HgbA1c levels 6.5 % was significantly higher for both tacrolimus formulations compared to CsA ; 41.1 % ( Astagraf XL ) , 33.6 % ( Prograf ) , and 21.3 % ( CsA ) .